Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-10-17 09:02:18 UTC |
---|
Update Date | 2022-03-07 02:49:25 UTC |
---|
HMDB ID | HMDB0005021 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Quetiapine |
---|
Description | The most common side effect is sedation, and is prescribed specifically for this effect in patients with sleep disorders. Seroquel will put the patient into a drowsy state, and will help the patient fall asleep. It is one of the most sedating of all anti psychotic drugs, rivaling even the most sedating older antipsychotics. Many prescriptions call for the entire dose to be taken before bedtime because of its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes including insomnia or the treatment of anxiety disorders. Due to its sedative side effects, reports of quetiapine abuse (sometimes by insufflating crushed tablets) have emerged in medical literature; Quetiapine belongs to a series of neuroleptics known as "atypical antipsychotics", which have become increasingly popular alternatives to "typical antipsychotics" such as haloperidol. Quetiapine HAS approvals for the treatment of schizophrenia and acute mania in bipolar disorder. It is also used off-label to treat other disorders, such as post-traumatic stress disorder, alcoholism, obsessive compulsive disorder, anxiety disorders, hallucinations in Parkinson's disease patients using ropinirole, and as a sedative for those with sleep disorders. The most common side effect is sedation, and is prescribed specifically for this effect in patients with sleep disorders. Seroquel will put the patient into a drowsy state, and will help the patient fall asleep. It is one of the most sedating of all anti psychotic drugs, rivaling even the most sedating older antipsychotics. Many prescriptions call for the entire dose to be taken before bedtime because of its sedative effects. Although quetiapine is approved by the FDA for the treatment of schizophrenia and bipolar disorder, it is frequently prescribed for off-label purposes including insomnia or the treatment of anxiety disorders. Due to its sedative side effects, reports of quetiapine abuse (sometimes by insufflating crushed tablets) have emerged in medical literature; for the same reason, abuse of other antipsychotics, such as chlorpromazine (Thorazine), may occur as well, but research related to the abuse of typical antipsychotics is limited. for the same reason, abuse of other antipsychotics, such as chlorpromazine (Thorazine), may occur as well, but research related to the abuse of typical antipsychotics is limited. |
---|
Structure | OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12 InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2 |
---|
Synonyms | Value | Source |
---|
2-[2-(4-Dibenzo[b,F][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol | ChEBI | Quetiapina | ChEBI | Quetiapinum | ChEBI | Norsic | Kegg | Quetiapine fumarate | HMDB | Seroquel | HMDB | Ethanol, 2-(2-(4-dibenzo(b,F)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (e)-2-butenedioate (2:1) (salt) | HMDB | Fumarate, quetiapine | HMDB | 2-(2-(4-Dibenzo(b,F)(1,4)thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol | HMDB |
|
---|
Chemical Formula | C21H25N3O2S |
---|
Average Molecular Weight | 383.507 |
---|
Monoisotopic Molecular Weight | 383.166747749 |
---|
IUPAC Name | 2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol |
---|
Traditional Name | quetiapine |
---|
CAS Registry Number | 111974-69-7 |
---|
SMILES | OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12 |
---|
InChI Identifier | InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2 |
---|
InChI Key | URKOMYMAXPYINW-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as dibenzothiazepines. Dibenzothiazepines are compounds containing a dibenzothiazepine moiety, which consists of two benzene connected by a thiazepine ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzothiazepines |
---|
Sub Class | Dibenzothiazepines |
---|
Direct Parent | Dibenzothiazepines |
---|
Alternative Parents | |
---|
Substituents | - Dibenzothiazepine
- Diarylthioether
- Aryl thioether
- N-alkylpiperazine
- 1,4-diazinane
- Piperazine
- Benzenoid
- Imidolactam
- Tertiary amine
- Tertiary aliphatic amine
- Azacycle
- Carboxylic acid amidine
- Dialkyl ether
- Ether
- Amidine
- Organic 1,3-dipolar compound
- Thioether
- Propargyl-type 1,3-dipolar organic compound
- Organonitrogen compound
- Organopnictogen compound
- Organooxygen compound
- Hydrocarbon derivative
- Primary alcohol
- Alcohol
- Organic nitrogen compound
- Organic oxygen compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Not Available | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatized |
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Quetiapine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0007-9264000000-4758f7f7f4947282ccbb | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Quetiapine GC-MS (1 TMS) - 70eV, Positive | splash10-0fdo-9543200000-188eddba94dd2a57f908 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Quetiapine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Quetiapine DI-ESI-qTof , Negative-QTOF | splash10-001i-0039000000-6e58caa07d6f7951f23e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quetiapine , positive-QTOF | splash10-001i-0089000000-b7b1c7d0bf6bb604c5cb | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quetiapine , positive-QTOF | splash10-0uk9-1390000000-ce855b6e08dee583681b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Quetiapine 35V, Positive-QTOF | splash10-0ul0-0092000000-b8ad82fb58fb41b6f4fa | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quetiapine 10V, Positive-QTOF | splash10-001i-0019000000-380bdfab40abc4fe9104 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quetiapine 20V, Positive-QTOF | splash10-00e9-2019000000-9a9f0ea1ddcfe3e51fba | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quetiapine 40V, Positive-QTOF | splash10-0a4i-6942000000-82ff888287705b61f40d | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quetiapine 10V, Negative-QTOF | splash10-001i-1039000000-026ca51b770ab0fc287d | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quetiapine 20V, Negative-QTOF | splash10-001l-2019000000-503cee9b3e7cc04ade6a | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quetiapine 40V, Negative-QTOF | splash10-08fu-9710000000-457979a8d0088bdeade2 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quetiapine 10V, Positive-QTOF | splash10-001i-0009000000-e07800842abb48579469 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quetiapine 20V, Positive-QTOF | splash10-000x-0019000000-f62857d5511d39f2c201 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quetiapine 40V, Positive-QTOF | splash10-0w29-0191000000-5ce92b5e3a22486cc2f2 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quetiapine 10V, Negative-QTOF | splash10-001i-1009000000-74ca90c52d883a3f4f25 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quetiapine 20V, Negative-QTOF | splash10-0a4l-9027000000-059f5ab035332d4b8f68 | 2021-09-22 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Quetiapine 40V, Negative-QTOF | splash10-01p6-2192000000-1ea11b461430b2f762a1 | 2021-09-22 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Membrane (predicted from logP)
|
---|
Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
|
---|
Tissue Locations | |
---|
Pathways | |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 20.7 (1.04-198.0) uM | Adult (>18 years old) | Both | Quetiapine poisoning | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0783 (0.00157-0.146) uM | Adult (>18 years old) | Both | schizophrenia (CYP2D6) | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0809 (0.00157-0.146) uM | Adult (>18 years old) | Not Specified | schizophrenia (CYP3A4 rs4646437) | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0626 (0.00157-0.146) uM | Adult (>18 years old) | Not Specified | schizophrenia (CYP3A5) | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 0.0652 (0.00157-0.146) uM | Adult (>18 years old) | Not Specified | schizophrenia (CYP3A7) | | details |
|
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 uM | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities | Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Quetiapine poisoning |
---|
- Flammia DD, Valouch T, Venuti S: Tissue distribution of quetiapine in 20 cases in Virginia. J Anal Toxicol. 2006 May;30(4):287-92. [PubMed:16803670 ]
|
|
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB01224 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB023592 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 4827 |
---|
KEGG Compound ID | C07397 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Quetiapine |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 5002 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 8707 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Bozsing, Daniel; Kovanyine, Lax Gyoergyi; Simig, Gyula; Rakoczy, Gyoergyne; Toempe, Peter; Krasznai, Gyoergy; Vereczkeyne, Donath Gyoergyi; Nagy, Kalman. A process for the preparation of quetiapine and its intermediates. 2001, Patent WO2001055125A1 (https://patents.google.com/patent/WO2001055125A1/en) |
---|
Material Safety Data Sheet (MSDS) | Not Available |
---|
General References | - Parker DR, McIntyre IM: Case studies of postmortem quetiapine: therapeutic or toxic concentrations? J Anal Toxicol. 2005 Jul-Aug;29(5):407-12. [PubMed:16105271 ]
- Stip E, Fahim C, Mancini-Marie A, Bentaleb LA, Mensour B, Mendrek A, Beauregard M: Restoration of frontal activation during a treatment with quetiapine: an fMRI study of blunted affect in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jan;29(1):21-6. Epub 2004 Nov 5. [PubMed:15610941 ]
- Langman LJ, Kaliciak HA, Carlyle S: Fatal overdoses associated with quetiapine. J Anal Toxicol. 2004 Sep;28(6):520-5. [PubMed:15516308 ]
- Stephan PL, Jaquenoud Sirot E, Mueller B, Eap CB, Baumann P: Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity. Pharmacopsychiatry. 2006 Jul;39(4):150-2. [PubMed:16871470 ]
- Fahim C, Stip E, Mancini-Marie A, Gendron A, Mensour B, Beauregard M: Differential hemodynamic brain activity in schizophrenia patients with blunted affect during quetiapine treatment. J Clin Psychopharmacol. 2005 Aug;25(4):367-71. [PubMed:16012281 ]
|
---|